Skip to main
JNJ
JNJ logo

JNJ Stock Forecast & Price Target

JNJ Analyst Ratings

Based on 29 analyst ratings
Buy
Strong Buy 31%
Buy 21%
Hold 48%
Sell 0%
Strong Sell 0%

Bulls say

Johnson & Johnson's pharmaceutical division is demonstrating significant potential for growth, particularly with icotrokinra, which has achieved a notable 30.2% clinical remission rate compared to 11.1% for the placebo, reinforcing its position as a transformative asset in the immunology pipeline. The management anticipates over $5 billion in annual peak sales for icotrokinra, driven by its efficacy, safety profile, and convenience of administration, indicating a strong strategic outlook in addressing unmet needs within the inflammatory bowel disease (IBD) and psoriasis markets. Additionally, the company's manufacturing capabilities and competitive edge in a crowded market further enhance the potential for robust financial performance moving forward.

Bears say

Johnson & Johnson's recent divestment of its consumer business, Kenvue, in 2023 eliminates a diversified revenue stream, concentrating all sales into its pharmaceutical and medical device divisions. This shift, along with the company's heavy reliance on the U.S. market, where over half of its revenue is generated, exposes it to potential regulatory and market risks inherent in the domestic landscape. Additionally, ongoing challenges within the pharmaceutical division's therapeutic areas may lead to future revenue volatility, dampening investor confidence in the stock's stability.

JNJ has been analyzed by 29 analysts, with a consensus rating of Buy. 31% of analysts recommend a Strong Buy, 21% recommend Buy, 48% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Johnson & Johnson and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Johnson & Johnson (JNJ) Forecast

Analysts have given JNJ a Buy based on their latest research and market trends.

According to 29 analysts, JNJ has a Buy consensus rating as of Aug 25, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $161.76, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $161.76, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Johnson & Johnson (JNJ)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.